The company focuses on non-fusion spinal implant technology. Its proprietary coflex Interlaminar Technology is indicated for use in one- or two-level lumbar stenosis from L1-L5 in adult patients.
In July, the company published two separate independent prospective clinical studies that examined the short-and long-term durability of coflex interlaminar stabilization.
More articles on devices:
Alphatec Spine 3Q revenue up 2%: 10 key concepts
NuVasive’s 3Q revenue up 12.3%: 10 things to know
Zimmer Biomet names new leaders
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
